The Immunohistochemical Study of Stathmin-1 as A Prognostic Factor In Non-small cell Lung Carcinoma

Nadhema B. Wetwet; Hadeel A. Kerbel; Ali S. Baay; Muhammed W. Al-Obaidy

doi:10.32007/jfacmedbagdad.6441948

Authors

Nadhema B. Wetwet AlSadiq Teaching Hospital, Babylon Health Directorate, Babil, Iraq
Hadeel A. Kerbel Department of Clinical Pathology, Medical College of Hammurabi, University of Babylon. Babil, Iraq.
Ali S. Baay Department Medicine, Medical College of Hammurabi, University of Babylon, Babil, Iraq.
Muhammed W. Al-Obaidy Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq.

DOI:

https://doi.org/10.32007/jfacmedbagdad.6441948

Keywords:

Immunohistochemistry, Lung Cancer, Stathmin 1

Abstract

Background: The cell cycle progression and cell motility are mainly controlled by a major microtubule depolymerising protein called Stathmin1 (also known as metablastin). Stathmin1 has been found to be up-regulated in some cancers and correlated with cell differentiation and proliferation.
Objectives: To evaluate the role of immunohistochemical expression of stathmin1 in non-small lung carcinoma and its correlation to different prognostic factors or parameters.
Materials & Methods: This retrospective study carried on 50 cases of small lung carcinomas (surgical specimens of lung tumours embedded in formalin-fixed paraffin). Applying the immunohistochemical techniques by using the primary antibodies to Stathmin1. Statistical analysis was done, and an assessment of correlation with different clinical and pathological parameters was measured.
Results: The results revealed Fifty cases of non-small lung carcinomas were subgrouped as 42% adenocarcinoma, 44% squamous cell carcinoma, 10%adeno-squamous,s and 4% non-small lung carcinoma , 84 % were Stathmin-1 positive, but there is nostatisticaly correlation between Stathmin-1 expression with age and patients' gender but Stathmin-1 expression correlated with parameters including type and grade of tumor. High expression was noted in poorly differentiated tumours.
Conclusion: From these results, we conclude that measurement of stathmin1 may be a beneficial prognostic biomarker for lung tumours, those poorly differentiated tumours. Stathmin1 expression in non-small cell lung carcinoma significantly correlated with poor tumor differentiation and could be considered an independent prognostic factor

Downloads

Download data is not yet available.

References

Ferlay j, Soerjomataram I, Ervic M, Dikshit R, Eser S, Mathers C et al. Globocan2012v1.0, Cancer Incidence and Mortality Worldwide:IARC CancerBase No.11.

Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24(5):653-664. https://doi.org/10.1038/modpathol.2010.232.

Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin prevents the transition from a normal to an endomitotic cell cycle during megakaryocytic differentiation. Cell Cycle (Georgetown, Tex) 2005;4(12):1774-82. https://doi.org/10.4161/cc.4.12.2171.

Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007;26(7):1003-12 17. https://doi.org/10.1038/sj.onc.1209864.

Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001;11(1):41-9. https://doi.org/10.1089/108729001750072119.

Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006; 209:549-558. https://doi.org/10.1002/path.2011.

Biaoxue R, Liu Hua, Fu Tian, Gao Wenlong, Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma. Japanese Journal of Clinical Oncology, Volume 47, Issue 4, April 2017, 342-349.

https://doi.org/10.1093/jjco/hyx005

Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer. 2006;94: 717-23. https://doi.org/10.1038/sj.bjc.6602991.

Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 2011; 15:1249-66. https://doi.org/10.1517/14728222.2011.620951.

Yurong L, Rong Biaoxue, Li Wei et al. Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma: Oncotarget. 2017; 8:16 ,26000-26012. https://doi.org/10.18632/oncotarget.11006.

Biaoxue R, Increased stathmin in serum as a potential tumor marker for lung adenocarcinoma. Japanese Journal of Clinical Oncology. 2017; 7: 47 668-668. https://doi.org/10.1093/jjco/hyx078.

Shimizu K. Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery. 2017:4,154, 1406-1417. https://doi.org/10.1016/j.jtcvs.2017.03.125.